DPP4 and type 2 diabetes mellitus: In addition, a comparison between DPP-IV inhibitors and sulfonylureas also showed a more significant reduction in MAGE for DPP-IV inhibitors in T2DM patients (MD = −14.93; 95% CI = −21.60 to −8.26; p < 0.0001, Fig. 3).